방사선종양학

본문글자크기
  • [Cancer Res Treat.] EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.

    성균관의대 / 박송이, 노재명, 안명주*

  • 출처
    Cancer Res Treat.
  • 등재일
    2019 Apr
  • 저널이슈번호
    51(2):493-501. doi: 10.4143/crt.2018.125. Epub 2018 Jun 18.
  • 내용

    바로가기  >

    Abstract
    PURPOSE:
    This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT).

    Materials and Methods:
    From January 2008 to December 2013, the medical records of 197 patients with stage III non- squamous non-small cell lung cancer treated with definitive CCRT were analyzed to determine progression-free survival (PFS) and overall survival (OS) according to EGFR mutation status.

    RESULTS:
    Among 197 eligible patients, 81 patients were EGFR wild type, 36 patients had an EGFR mutation (exon 19 Del, n=18; L858R, n=9, uncommon [G719X, L868, T790M], n=9), and 80 patients had unknown EGFR status. The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty-four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the EGFR mutation group, 11.8 months for EGFR wild type, and 10.5 months for the unknown EGFR group (p=0.013 and p=0.042, respectively). The most common site of metastasis in the EGFR mutant group was the brain. However, there was no significant difference in OS among the three groups (34.6 months for EGFR mutant group vs. 31.9 months for EGFR wild type vs. 22.6 months for EGFR unknown group; p=0.792 and p=0.284). A total of 29 patients (80.6%) with EGFR mutation were treated with EGFR tyrosine kinase inhibitor (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) upon progression.

    CONCLUSION:
    EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.

     


    Author information

    Park SE1, Noh JM2, Kim YJ3, Lee HS3, Cho JH3, Lim SW3, Ahn YC2, Pyo H2, Choi YL4, Han J4, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
    1
    Division of Hematology-Oncology, Department of Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
    2
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    3
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
    4
    Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

  • 키워드
    Chemoradiotherapy; EGFR mutation; Non-squamous non-small cell lung cancer; Stage III; Survival
  • 덧글달기
    덧글달기
       IP : 44.222.129.73

    등록